Teva Pharmaceutical Industries Ltd. expects to file regulatory applications for a fully substitutable generic version of GlaxoSmithKline PLC’s top-seller Advair Diskus (fluticasone/salmeterol) in the U.S. and Europe in 2017, positioning the product for launch in 2018, management said during a respiratory-focused R&D presentation Oct. 8.
This is a reversal of Teva’s earlier position on the viability of developing a fully substitutable generic Advair and reflects...